Rubicon Partners with Diagenode for ChIP Sample Preparation
News Nov 05, 2012
Rubicon Genomics, Inc. has announced that it has partnered with Diagenode SA to integrate Rubicon’s ThruPLEX™ technology into Diagenode’s epigenetics platforms to increase the efficiency and quality of DNA sample preparation for chromatin immunoprecipitation (ChIP) applications.
The new agreement allows Diagenode to incorporate the Rubicon ThruPLEX-FD technology into its new MicroPLEX Library Preparation Kit for ChIP-seq studies requiring very small amounts of sample.
Rubicon is a leading provider of sample-specific pre-analytical processes to improve the performance and capabilities of DNA analytical platforms.
Its ThruPLEX-FD NGS Prep kits for synthesis and amplification of ChIP DNA for next generation sequencing (NGS) use a one-tube, three-step process that is efficient, fast, and produces high quality DNA from small samples.
Diagenode’s products increase the efficiency and speed of the process used to precipitate and recover DNA for ChIP applications from very small amounts of chromatin.
The combination of these two patented technologies will decrease the time and labor needed for ChIP-sequencing by almost 10 hours and provide researchers with high quality ChIP-seq and ChIP-chip results from small samples, reducing the number of cells needed to conduct ChIP analyses by a minimum of 100-fold.
“This partnership with Diagenode extends the reach of our proprietary technology. Diagenode is a leader in the ChIP market and our ThruPLEX technology is ideal for use in ChIP studies. This partnership is an important example of our collaboration strategy that focuses on combining complementary technologies to offer complete solutions to the research community,” noted James Koziarz, CEO of Rubicon Genomics.
Rubicon intends to complete additional non-exclusive distribution agreements with leaders in other segments of the growing market for DNA and RNA analysis.
Diagenode has developed and validated reagents and equipment that reduce the number of cells needed to conduct analyses by 10 to 100-fold.
This allows researchers to grow or harvest fewer cells, decreasing time and expense, and also enables studies of small subpopulations of cells.
Combining these properties with the advantages of ThruPLEX-FD increases the quality of the sequencing results and is expected to enhance the value of ChIP as a tool for epigenomic research.
“We are pleased to add the Rubicon ThruPLEX technology to Diagenode’s high quality product line for ChIP studies,” said Didier Allaer, CEO and Founder of Diagenode. “It’s fast, easy-to-use and sensitive, producing high quality results from challenging samples. We will also offer the MicroPLEX and True MicroChIP kits to our customers in conjunction with our new SX-8G IP-Star® Automated System, the first comprehensive system to automate ChIP and DNA methylation assays.”
Rubicon’s ThruPLEX technology incorporates a streamlined one-tube, three-step process without intermediate purifications, transfers, columns or gels. The reduced steps and material transfers decrease the likelihood of experimental variability, bias and contamination.
ThruPLEX technology is designed and validated for use with samples as small as 50 picograms of human DNA and can be used in plasma, FFPE, cDNA, ChIP and population studies.
The kits are currently available for sequencing on Illumina® HiSeq®, MiSeq® and Genome Analyzer instruments. The technology is also being developed for additional formats and platforms.
Both Rubicon and Diagenode will be exhibiting at the Annual Meeting of the American Society for Human Genetics to be held in San Francisco, CA, November 6-10, 2012.
To learn more about Rubicon’s ThruPLEX and its other sample-specific pre-analytical technologies, visit Booth #803, and to learn more about Diagenode’s technologies, visit Booth #406.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018